PTS Diagnostics Unveils New Capillary Tube

PTS Diagnostics Unveils New Capillary Tube

Advanced blood collection technology combines speed, efficiency and savings

Indianapolis – January 21, 2015 – PTS Diagnostics, the U.S.-based manufacturer of both the CardioChek® brand and the A1CNow® family of point-of-care diagnostic products, today announced that it has launched a line of capillary tubes using a new and innovative technology. The PTS Diagnostics Capillary Tubes, which provide speed, efficiency and savings — especially for applications where exact sample volumes are required — are now available from PTS Diagnostics’ distributors around the world.

PTS Diagnostics Capillary Tubes provide better efficiency and are designed to be easier to use than traditional blood transfer tubes. Using a single glass tube with plastic casing, the PTS Diagnostics Capillary Tubes provide consistent selfwicking technology to deliver preset volumes. This improved design is perfect for blood collection needs addressing a wide range of applications across many different medical devices. In addition, the new PTS Diagnostics Capillary Tubes provide significant savings over traditional pipettes with the same or better quality.

These new PTS Diagnostics Capillary Tubes can increase efficiency in workflow by providing: 

  • Ease-of-use with no assembly
  • One-hand blood collection and dosing
  • A glass tube to ensure easy blood collection
  • Bulb-squeeze dispensing technology that ensures consistent performance
  • Only one item to inventory (no plunger)
  • “In the health screening, workplace health and physician office environments, this new design provides many advantages over traditional blood transfer tubes,” said Robert Huffstodt, President and CEO of PTS Diagnostics. “PTS Diagnostics Capillary Tubes are ideal for low volume blood collection given the product’s one-hand operation, no assembly and precise self-wicking collection to preset volumes. This new technology combines speed, efficiency and savings.”

    These new capillary tubes are designed to be easy-to-use and require little additional training.

    “PTS Diagnostics is known for its lipid testing and A1C monitoring devices, however this new product will help us expand our reach across point-of-care testing as the new capillary tubes provide savings and efficiency across many tests including ABO/Rh Blood, IgE, HIV, hepatitis and various other infectious diseases to name a few,” said Huffstodt.

    PTS Diagnostics’ handheld, highly-accurate, fast, and economical diagnostic devices empower the medical community to quickly measure HbA1c and glucose, and generate a lipid (cholesterol) profile, all at the point of care.

    PTS Diagnostics’ portfolio includes the following systems:

  • CardioChek professional analyzers address the connection between heart attack, stroke, and diabetes by providing on-site lipid panel (total cholesterol, HDL cholesterol, and triglycerides) screening results in as little as 90 seconds and can also measure glucose. CardioChek professional analyzers calculate LDL cholesterol, the TC/HDL ratio, the LDL/HDL ratio, and non-HDL cholesterol.
  • The A1CNow+ system provides healthcare professionals with a fast, easy, and accurate method of obtaining HbA1c results while the patient is in the exam room. In just five minutes, clinicians have information to provide an immediate consultation with a patient. The A1CNow+ system is critical to diabetes management and is fully reimbursable.
  • About PTS Diagnostics – PTS Diagnostics is a global provider of point-of-care diagnostic products to the healthcare industry. Headquartered in Indianapolis, Indiana, PTS Diagnostics designs, manufactures, and markets products for distribution in over 120 countries around the world. The company has sales offices in Europe, Latin America, and the Pacific Rim. PTS Diagnostics’ products include both the CardioChek systems and A1CNow systems.

    All trademarks used or mentioned in this release are protected by law.

    For more information, visit www.ptsdiagnostics.com or contact Tom Wiser at +1-317-870-5610.

    MKG001159 Rev. 0 1/15

    PTS Diagnostics Presents at J.P. Morgan Healthcare & Biotech Showcase 2015

    PTS Diagnostics Presents at J.P. Morgan Healthcare & Biotech Showcase 2015

    Indianapolis – Jan. 27, 2015 – PTS Diagnostics, the U.S.-based manufacturer of both the CardioChek® brand and the A1CNow® family of point-of-care diagnostic products, was invited to present at the 33rd Annual J.P. Morgan Healthcare Conference & Biotech Showcase 2015 held the week of January 12 in San Francisco. The company’s presentation emphasized its industry-leading growth, its global distribution network with market leadership in many key countries, and its pipeline of innovative new products.

    The Biotech Showcase is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to and meet with peers, investors, and pharmaceutical executives during the course of one of the industry’s largest annual healthcare investor conferences. Investors and biopharmaceutical executives from around the world gather each year to do what is widely viewed as setting the tone for the coming year.

    PTS Diagnostics was among best-in-class biotechnology and life science companies that presented to the more than 3,700 investors who attended the event. PTS Diagnostics’ products are sold in more 120 countries and its CardioChek analyzers have screened more than 120 million people worldwide.

    “In 2014, PTS Diagnostics delivered revenue growth in excess of 40 percent resulting in a 5-year CAGR of greater than 25 percent. Our innovation pipeline will bring several exciting products to market in 2015,” said Robert Huffstodt, President and CEO of PTS Diagnostics. “Our core products test for important health indicators in the fastest growing global pointof-care testing segments (lipids and diabetes). We offer the only truly globally-available point-of-care solution for lipid testing with our CardioChek analyzers and test strips. In addition, sales of our A1CNow System surpassed 1 million tests in just 8 months since we acquired the A1C monitoring device.”

    PTS Diagnostics products are manufactured in the United States, where it maintains facilities in the Midwest and Silicon Valley. The company’s 91 US and international patents and 86 pending patent applications place the company in a prime position to continue to work with the healthcare community to test more patients. Further, the company has entered into private label manufacturing agreements with major US pharmacies and retailers.

    “PTS Diagnostics has built an expert medical device leadership team. Combined with the efforts of more than 3,000 medical distributor sales representative in the US alone, PTS Diagnostics is continuing to rapidly grow market share both domestically and abroad,” said Huffstodt.

    PTS Diagnostics recently announced the launch of new technology for small-volume blood collection via its PTS Diagnostics™ Capillary Tubes, and has developed a wellness portal and health risk assessment software package to increase the quality of communication between patients and medical professionals.

    “We continue to unveil new sources of growth such as pharma services, and the development of software such as the PTS Connect™ Wellness Portal, which will change the way screening participants will communicate with wellness programs,” concluded Huffstodt. “We look forward to the future as we continue to innovate point-of-care testing through our people, technology and service.”

    PTS Diagnostics’ handheld, highly-accurate, fast, and economical diagnostic devices empower the medical community to quickly measure HbA1c and glucose, and generate a lipid (cholesterol) profile, all at the point of care.

    PTS Diagnostics’ portfolio includes the following systems:

  •  CardioChek professional analyzers address the connection between heart attack, stroke, and diabetes by providing on-site lipid panel (total cholesterol, HDL cholesterol, and triglycerides) screening results in as little as 90 seconds and by measuring glucose. CardioChek professional analyzers calculate LDL cholesterol, the TC/HDL ratio, the LDL/HDL ratio, and non-HDL cholesterol.
  • The A1CNow+ system provides healthcare professionals with a fast, easy, and accurate method of obtaining HbA1c results while the patient is in the exam room. In just five minutes, clinicians have information to provide an immediate consultation with a patient. The A1CNow+ system is critical to diabetes management and is fully reimbursable.
  • About PTS Diagnostics – PTS Diagnostics is a global provider of point-of-care diagnostic products to the healthcare industry. Headquartered in Indianapolis, Indiana, PTS Diagnostics designs, manufactures, and markets products for distribution in over 120 countries around the world. The company has sales offices in Europe, Latin America, and the Pacific Rim. PTS Diagnostics’ products include both the CardioChek systems and A1CNow systems.

    All trademarks used or mentioned in this release are protected by law.

    For more information, visit www.ptsdiagnostics.com or contact Tom Wiser at +1-317-870-5610.

    MKG001303 Rev. 0 1/15

    PTS Diagnostics Announces 14 New US and International Patents

    PTS Diagnostics Announces 14 New US and International Patents

    Proprietary technologies drive innovation in point-of-care testing

    Indianapolis – Feb. 25, 2015 – PTS Diagnostics, the U.S.-based manufacturer of both the CardioChek® brand and the A1CNow® family of point-of-care diagnostic products, has been granted 4 new U.S. patents and 10 new patents from Canada, Europe, Germany, India, Korea, and Mexico in just the last 18 months. Since mid-2013, PTS Diagnostics was awarded 5 patents related to its CardioChek test strips, 8 for its A1CNow+ system and one for a new test strip that can test multiple blood chemistries at the same time.

    “We continue to develop new and alternative innovations for our CardioChek test strip technology in the US and continue to be granted patents around the globe as we expand distribution of our A1CNow+ system to additional countries,” said Robert Huffstodt, President and CEO of PTS Diagnostics. “This technology ensures we deliver accurate and precise lipid, glucose and A1C testing and monitoring.”

    In approximately the last 18 months, PTS Diagnostics was granted these new patents:

  • United States: #8,460,539; #8,465,696; #8,642,320; #8,865,089
  • Canada: #2,654,292
  • Europe: #1 474 692; #1 725 650; #2 221 621
  • Germany: #112,012,000,32
  • Korea: #10-1,324,375, #10-1,347,472
  • India: #258,142; #257,235
  • Mexico: #315,864
  • PTS Diagnostics currently holds 91 U.S. and international patents and has 86 pending patent applications.

    “As we look to the future, we are anticipating the needs of our customers and are working diligently to create next-generation technology to expand the testing and services we provide,” said Huffstodt. “These new patents, combined with our pending applications, will fuel PTS Diagnostics’ growth in the future. We continue to have a robust pipeline of new innovation and look forward to the next year and beyond.”

    PTS Diagnostics’ products are sold in more than 120 countries and its CardioChek analyzers have screened more than 120 million people worldwide. In addition, sales of its A1CNow System surpassed 1 million tests in just 8 months after the company began manufacturing the A1C monitoring device.

    PTS Diagnostics’ handheld, highly-accurate, fast, and economical diagnostic devices empower the medical community to quickly measure HbA1c and glucose, and generate a lipid (cholesterol) profile, all at the point of care.

    PTS Diagnostics’ portfolio includes the following systems:

  •  CardioChek professional analyzers address the connection between heart attack, stroke, and diabetes by providing on-site lipid panel (total cholesterol, HDL cholesterol, and triglycerides) screening results in as little as 90 seconds and can also measure glucose. CardioChek professional analyzers calculate LDL cholesterol, the TC/HDL ratio, the LDL/HDL ratio, and non-HDL cholesterol.
  •  The A1CNow+ system provides healthcare professionals with a fast, easy, and accurate method of obtaining HbA1c results while the patient is in the exam room. In just five minutes, clinicians have information to provide an immediate consultation with a patient. The A1CNow+ system is critical to diabetes management and is fully reimbursable.
  • About PTS Diagnostics – PTS Diagnostics is a global provider of point-of-care diagnostic products to the healthcare industry. Headquartered in Indianapolis, Indiana, PTS Diagnostics designs, manufactures, and markets products for distribution in over 120 countries around the world. The company has sales offices in Europe, Latin America, and the Pacific Rim. PTS Diagnostics’ products include both the CardioChek systems and A1CNow systems.

    All trademarks used or mentioned in this release are protected by law.

    For more information, visit www.ptsdiagnostics.com or contact Tom Wiser at +1-317-870-5610.

    MKG001306 Rev. 0 2/15

    PTS Diagnostics Introduces Secure Cloud-Based Solution Enhancing Corporate Wellness Programs and Improving Health Screeners' Productivity

    PTS Diagnostics Introduces Secure Cloud-Based Solution Enhancing Corporate Wellness Programs and Improving Health Screeners’ Productivity

    PTS Connect™ Wellness Solution is an online tool that digitizes data from screening events and promotes employee engagement in corporate wellness programs

    Indianapolis, March 10, 2015 – PTS Diagnostics, the U.S.-based manufacturer of both the CardioChek® brand and the A1CNow® family of point-of-care diagnostic products, announces the launch of the PTS Connect™ Wellness Solution. This secure cloud-based solution will empower health screening companies to screen more individuals faster and corporate wellness programs to improve outcomes by encouraging participants to monitor and track activity and progress online. In addition, it enables population health management by targeting wellness communication and aggregating data for at-risk individuals.

    In short, the PTS Connect Wellness Solution provides an opportunity to improve productivity, participant engagement and data analysis among organizations that manage wellness screenings and wellness programs.

    “The PTS Connect Wellness Solution is the complete Population Health Management tool. As a software solution for screening and wellness programs, the new online tool meets the needs of customers with a variety of goals,” said Robert Huffstodt, President and CEO of PTS Diagnostics. “Some customers may simply want to automate the acquisition of biometric results, provide immediate screening reports to participants
    and aggregate data. Others may want to grant online access to participants after the screening event, providing online education and enabling targeted wellness messaging. This flexible solution allows customers to grow their wellness platform over time to meet changing needs.”

    For health screeners, the software is capable of automated upload of biometric information from a CardioChek lipid and glucose analyzer, and from a weight scale, blood pressure monitor and pedometer. The biometric data is stored securely and can be synced instantaneously with a participant’s online wellness account.

    For corporate wellness programs, PTS Connect Wellness Solution offers a turnkey range of online tools and resources supporting healthy lifestyle change. PTS Connect offers a personal health assessment that produces wellness education based on individual needs. In addition, users can track and monitor physical activity over time. Educational offerings include quizzes, calculators, self-assessments and decision guides.

    “Our new platform was designed for screeners and corporate wellness programs,” said Huffstodt. “We have taken the entire health management continuum and created an online software solution to make screening and running a corporate wellness program easy. We are excited to begin offering these solutions via our global distribution network.”

    In addition to PTS Connect Wellness Solution, PTS Diagnostics’ portfolio includes the following systems:

  • CardioChek professional analyzers address the connection between heart attack, stroke, and diabetes by providing on-site lipid panel (total cholesterol, HDL cholesterol, and triglycerides) screening results in as little as 90 seconds and can also measure glucose. CardioChek professional analyzers calculate LDL cholesterol, the TC/HDL ratio, the LDL/HDL ratio, and non-HDL cholesterol.
  • The A1CNow+ system provides healthcare professionals with a fast, easy, and accurate method of obtaining HbA1c results while the patient is in the exam room. In just five minutes, clinicians have information to provide an immediate consultation with a patient. The A1CNow+ system is critical to diabetes management and is fully reimbursable.
  • About PTS Diagnostics – PTS Diagnostics is a global provider of point-of-care diagnostic products to the healthcare industry. Headquartered in Indianapolis, Indiana, PTS Diagnostics designs, manufactures, and markets products for distribution in over 120 countries around the world. The company has sales offices in Europe, Latin America, and the Pacific Rim. PTS Diagnostics’ products include both the CardioChek systems
    and A1CNow systems.

    All trademarks used or mentioned in this release are protected by law.

    For more information, visit www.ptsdiagnostics.com or contact Tom Wiser at +1-317-870-5610.

    MKG001343 Rev. 0 3/15

    PTS Diagnostics and Blinded Diagnostics Collaborate to Provide Encrypted Lipid and Glucose Biometric Measurements

    PTS Diagnostics and Blinded Diagnostics Collaborate to Provide Encrypted Lipid and Glucose Biometric Measurements

    Indianapolis, IN – May 13, 2015 – PTS Diagnostics, in partnership with Blinded Diagnostics, is providing encrypted point-of-care diagnostics and support services for an international phase III clinical trial. The trial is sponsored by a major global biopharmaceutical company in support of a
    new drug addressing lipidemia which impacts cardiometabolic diseases worldwide. The encrypted CardioChek Plus analyzer will be used throughout the clinical trial to monitor clinical decision points while providing increased efficiency in the form of improved timelines for both site investigators as well as participants.

    The CardioChek Plus analyzer, which provides lipid panel and glucose results in as little as 90 seconds, uses clinical trial industry-standard encryption for patient’s results. Encrypted results are then electronically sent for off-site decryption. Neither the patient nor the clinician performing the fingerstick test knows the results.

    “This point-of-care diagnostic technology will be utilized on two continents. As a component of the overall program, Blinded Diagnostics will train and provide support of all sites in the proper use and quality control of the devices for the trial,” said Steve Karuppan, CEO of Blinded Diagnostics. “This is just one example of how the partnership between PTS Diagnostics and Blinded Diagnostics can create efficiencies for pharmaceutical clinical development.”

    This application of point-of-care technology will change the paradigm for clinical trials.

    “This technology will provide much faster testing results to clinical trial’s contract service organizations,” said Robert Huffstodt, President and CEO of PTS Diagnostics. “We anticipate significant demand from the industry given our combined ability to quickly and accurately measure lipid results, securely encrypt measurements, send off-site and decrypt. This technological advance changes the landscape for clinical trials.”

    PTS Diagnostics’ product lines also include handheld, highly-accurate, fast and economical diagnostic devices that empower the medical community to quickly measure HbA1c and glucose, and generate a lipid (cholesterol) profile, all at the point of care:

  • The CardioChek Plus analyzer addresses the connection between heart attack, stroke, and diabetes by providing simultaneous on-site lipid panel (total cholesterol, HDL cholesterol, and triglycerides) and glucose screening results in as little as 90 seconds. The CardioChek Plus analyzer also calculates LDL cholesterol, the TC/HDL ratio, the LDL/HDL ratio, and non-HDL cholesterol.
  • The A1CNow+ system provides healthcare professionals with a fast, easy, and accurate method of obtaining HbA1c results while the patient is in the exam room. In just five  minutes, clinicians have information to provide an immediate consultation with a patient.
  • About PTS Diagnostics – PTS Diagnostics is a global provider of point-of-care diagnostic products to the healthcare industry. Headquartered in Indianapolis, Indiana, PTS Diagnostics designs, manufactures, and markets products for distribution in over 133 countries around the world. The company has sales offices in Europe, Latin America, and the Pacific Rim.

    About Blinded Diagnostics
    Blinded Diagnostics is a pioneering contract service organization specializing in sourcing and supporting point of care diagnostic test platforms that provide same day lab test results for pharmaceutical clinical trials. As an innovator with partners in point-of-care diagnostics, Blinded
    Diagnostics is at the forefront of a paradigm shift that brings flexibility and efficiency for trial sponsors. www.blindeddiagnostics.com.

    All trademarks used or mentioned in this release are protected by law.

    For more information, visit www.ptsdiagnostics.com or contact Tom Wiser at 317-870-5610.

    MKG001414 Rev. 0 4/15